Humacyte

Acellular Tissue Engineered Vessels are tissue structures designed to resemble the body’s natural vasculature and aim to restore, replace, or enhance the function of damaged or diseased vascular tissue.

Humacyte’s preclinical research includes investigations into Advanced Organ Systems beyond the Accellular Tissue Engineered Vessel (ATEV) platform.

Humacyte is exploring alternatives to urinary conduits, which currently use segments of the small intestine to divert urine after bladder removal.

Humacyte’s bioengineering technology creates universally implantable, regenerative tissues for treating injury and disease.

Ms. Sebelius is the Chair of the Humacyte Board of Directors and also serves as a member of the Nominating and Governance Committee. She is the Chief Executive Officer of Sebelius Resources LLC, which provides strategic advice to private companies, non-profit organizations, higher education institutions, and financial investors. In 2009, she was appointed Secretary of the U.S. Department of Health and Human Services (HHS) by President Barack Obama and served in that role until June 2014. Previou

A leading regenerative medicine company committed to driving change and improving patient outcomes

Humacyte assists healthcare professionals in accessing coding and reimbursement information.

Humacyte’s scalable platform produces off-the-shelf, universally implantable human tissues for treating injury, disease, and chronic conditions.

Humacyte Global, Inc. outlines privacy practices for personal information collected through its websites and online services.

Humacyte Global, Inc. develops tissue-engineered products to address unmet medical needs in vascular surgery and improve patient quality of life. Expanded Access allows investigational therapies to be used outside clinical trials.

The Transparency in Coverage Rule requires group health plans to disclose provider rates, out-of-network costs, and prescription drug pricing in machine-readable files.